Over the last 7 days, the market has remained flat, but over the past 12 months, it has risen by 18%, with earnings forecast to grow by 17% annually. In such a climate, finding stocks with strong balance sheets and solid fundamentals can be rewarding. Penny stocks may be a somewhat outdated term, but they continue to represent opportunities for growth at lower price points, particularly when they are backed by financial strength and clear potential for development.

Underneath we present a selection of stocks filtered out by our screen.

aTyr Pharma (ATYR)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: aTyr Pharma, Inc. is a clinical stage biotechnology company focused on developing therapies for fibrosis and inflammation by translating tRNA synthetase biology, with a market cap of $51.99 million.

Operations: aTyr Pharma does not report any distinct revenue segments.

Market Cap: $51.99M

aTyr Pharma, a clinical-stage biotech firm with a market cap of US$51.99 million, is navigating challenges typical of penny stocks. The company is pre-revenue, generating less than US$1 million annually, and remains unprofitable with a net loss of US$10.31 million in the recent quarter. Despite this, its focus on innovative therapies for fibrosis and inflammation shows potential; recent Phase 3 trials for efzofitimod indicate promising results in treating pulmonary sarcoidosis. However, volatility persists as the stock faces delisting risks from Nasdaq due to low share prices, although it has secured an extension to rectify this issue by November 2026.

INmune Bio (INMB)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: INmune Bio Inc. is a clinical-stage immunology company that develops drugs aimed at reprogramming the innate immune system to treat diseases in the United States, with a market cap of $65.50 million.

Operations: Currently, there are no reported revenue segments for this clinical-stage immunology company.

Market Cap: $65.5M

INmune Bio, a clinical-stage immunology firm with a market cap of US$65.50 million, is pre-revenue and unprofitable, reporting a net loss of US$1.27 million in the recent quarter. Despite financial challenges common among penny stocks, INmune Bio's advancements in its CORDStrom and XPro1595 platforms show promise. The company is progressing toward regulatory milestones for Ebstrocel in treating Recessive Dystrophic Epidermolysis Bullosa (RDEB) and has received FDA Fast Track designation for XPro1595 targeting Alzheimer's disease neuroinflammation. Recent establishment of a Scientific Advisory Board further bolsters its strategic positioning amid index reclassifications reflecting volatility inherent to this stock category.

Nu Skin Enterprises (NUS)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Nu Skin Enterprises, Inc. develops and distributes a range of beauty and wellness products globally, with a market cap of $232.19 million.

Operations: The company's revenue is primarily derived from its operations in the Americas ($258.55 million), Mainland China ($185.66 million), Southeast Asia/Pacific ($195.53 million), Japan ($164.93 million), Europe & Africa ($143.34 million), South Korea ($114.58 million), and Hong Kong/Taiwan ($114.94 million), along with contributions from Rhyz Investments' manufacturing segment totaling $217.99 million and other areas generating $16.31 million, all figures in millions of $.

Market Cap: $232.19M

Nu Skin Enterprises, with a market cap of US$232.19 million, has faced financial setbacks, reporting a net loss of US$249.8 million in Q2 2026 compared to a net income the previous year. Despite this, its debt is well-managed with operating cash flow covering 23.8% of it, and short-term assets exceeding both short and long-term liabilities. The company maintains an experienced board and management team but struggles with profitability challenges as losses have increased over five years at an annual rate of 41.2%. Recent executive changes may impact operations temporarily while dividend sustainability remains questionable given current earnings coverage issues.

Next Steps

• Embark on your investment journey to our 310 US Penny Stocks selection here.
• Ready For A Different Approach? The end of cancer? These 33 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.